Company Avidity Biosciences, Inc.

RNA

US05370A1088

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Avidity Biosciences, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
26.45 ^USD	+3.40%		+8.58%	+192.27%

04-04	Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	MT
04-04	Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	MT

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Number of employees: 253

USD in Million	2022	Weight	2023	Weight	Delta
Antibody Oligonucleotide Conjugates 100.0 %	9	100.0 %	10	100.0 %	+3.64%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	9	100.0 %	10	100.0 %	+3.64%

Managers	Title	Age	Since
Troy Wilson FOU	Founder	55	12/11/12
Sarah Boyce CEO	Chief Executive Officer	52	30/09/19
Michael MacLean DFI	Director of Finance/CFO	58	18/05/20
Steven G. Hughes CTO	Chief Tech/Sci/R&D Officer	57	22/02/22
W. Flanagan CTO	Chief Tech/Sci/R&D Officer	62	20/01/21
Arthur Levin BRD	Director/Board Member	70	30/09/13
Teresa McCarthy HRO	Human Resources Officer	60	31/07/20
Kathleen Gallagher PRN	Corporate Officer/Principal	-	31/03/21
Eric B. Mosbrooker PRN	Corporate Officer/Principal	46	24/08/21
John W. Wallen LAW	General Counsel	66	12/11/12

Members of the board	Title	Age	Since
Arthur Levin BRD	Director/Board Member	70	30/09/13
Carsten Boess BRD	Director/Board Member	57	12/04/20
Edward Kaye BRD	Director/Board Member	74	21/08/19
Sarah Boyce CEO	Chief Executive Officer	52	30/09/19
Jean J. Kim BRD	Director/Board Member	50	10/01/21
Troy Wilson FOU	Founder	55	12/11/12
Eric B. Mosbrooker PRN	Corporate Officer/Principal	46	24/08/21
Noreen Henig BRD	Director/Board Member	59	21/08/19
Tamar Thompson BRD	Director/Board Member	50	10/01/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	95,624,818	89,535,818 ( 93.63 %)	0	93.63 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 13.05 %	10,404,096	13.05 %	266 M $
T. Rowe Price Associates, Inc. (Investment Management) 12.11 %	9,656,852	12.11 %	246 M $
RTW Investments LP 9.921 %	7,909,269	9.921 %	202 M $
T. Rowe Price International Ltd. 8.671 %	6,912,661	8.671 %	176 M $
RTW Investments LP 8.392 %	6,689,789	8.392 %	171 M $
BlackRock Advisors LLC 7.703 %	6,141,013	7.703 %	157 M $
Cowen & Co. LLC 7.061 %	5,629,103	7.061 %	144 M $
BRISTOL-MYERS SQUIBB COMPANY 6.366 %	5,075,304	6.366 %	130 M $
Vanguard Fiduciary Trust Co. 5.072 %	4,043,179	5.072 %	103 M $
STATE STREET CORPORATION 4.313 %	3,438,328	4.313 %	88 M $

Avidity Biosciences, Inc.

10578 Science Center Drive Suite 125

92121, San Diego

http://www.aviditybiosciences.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.45 USD

Average target price

45.88 USD

Spread / Average Target

+73.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
AVIDITY BIOSCIENCES, INC.	+192.27%	2.53B
CSL LIMITED	-3.79%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals